ARVNArvinas, Inc.

1. Jun 22, 2026On June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”)Director or officer change · Form 8-K
2. Jun 16, 2026As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered …Other event · Form 8-K
3. Jun 2, 2026Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio.Regulation FD disclosure · Form 8-K
4. May 12, 2026Rigel License Agreement On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered …Material agreement entered · Form 8-K
5. May 1, 2026On May 1, 2026, the Company issued a press release announcing that the FDA has granted approval for VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of …Regulation FD disclosure · Form 8-K
6. Mar 18, 2026On March 18, 2026, the Company issued a press release announcing positive Phase 1 clinical trial data for ARV-102, an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK, showing greater than 50% LRRK2 degradation in the CSF of patients with …Regulation FD disclosure · Form 8-K
7. Feb 12, 2026Change in President, Chief Executive Officer and Chair of the Board of Directors On February 10, 2026, John Houston, Ph.D., notified Arvinas, Inc. (the “Company”) of his decision to resign as president, chief executive officer (“CEO”) and chairperson of the Company’s board of directors (the “Board”), effective …Director or officer change · Form 8-K
8. Dec 8, 2025On December 6, 2025, the Company issued a press release announcing preclinical data for ARV-393, a PROTAC BCL6 degrader, in combination with glofitamab, a CD20×CD3 bispecific antibody.Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.